This bill amends the Controlled Substances Act to expand prohibited acts to specifically include fentanyl , its analogues, and counterfeit substances , which are defined as drugs containing fentanyl, its analogue, or methamphetamine but falsely marketed under another product's identifying mark. This legislative change aims to strengthen the legal framework for prosecuting offenses involving these dangerous and deceptive substances. To address the proliferation of these drugs, the bill mandates the Drug Enforcement Administration (DEA) to establish a comprehensive operation and response plan within 180 days. This plan must detail strategies for federal law enforcement investigations and seizures, enhance education and prevention efforts tailored to youth, and audit existing public awareness campaigns for improved effectiveness. Furthermore, the legislation requires annual reports to Congress from the Attorney General, in consultation with the DEA and the Office of National Drug Control Policy. These reports will provide detailed data on the collection, seizures, charges, convictions, and sentences related to counterfeit fentanyl or methamphetamine substances , particularly those in pill form, along with federal prevention measures.